Global EditionASIA 中文雙語(yǔ)Fran?ais
    Business
    Home / Business / Companies

    US nod for BP medicine showcases China's pharma prowess

    By Liu Zhihua | China Daily | Updated: 2019-12-24 09:44
    Share
    Share - WeChat
    A technician carries out a test at a pharmaceutical company in Beijing. [Photo/Xinhua]

    The market approval by the United States of high blood pressure medicine Conjupri developed in China marked the fast-growing research and development capabilities of Chinese drug companies and their increasing presence abroad, industry analysts said.

    CSPC Pharmaceutical Group Ltd announced on Friday that the US Food and Drug Administration had granted market approval to its independently developed Conjupri (levoamlodipine maleate) tablets for the treatment of hypertension in adults and children 6 years and older. The company is based in Shijiazhuang, Hebei province.

    That makes Conjupri the first innovative drug from the Chinese mainland which has been granted full approval following a standard review by the FDA.

    It also paves the way for the Hong Kong-listed company to market the drug in other parts of the world, said Cai Dongchen, chairman of the company, who stressed it is important for Chinese pharmaceutical companies to grow stronger by taking part in global competition.

    The news inspired a strong advance of the firm's shares in Hong Kong. The company's stock ended at HK$18.62 ($2.38) on Monday, up 2.08 percent for the day.

    "The FDA approval reflects the international pharmaceutical community's higher recognition of Chinese drug quality," said Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy.

    "China used to have few self-developed original or innovative drugs, especially in new chemical compounds. But things are changing due to the improved regulatory environment and the stronger play of market mechanisms."

    China's medicine reforms in recent years are driving Chinese companies to focus more on new drug R&D and innovation to optimize product portfolios toward medium-to-high end returns, instead of simply profiting from the production and sales of low-quality generics, he said.

    China joined the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use, or ICH, in 2017.

    The group is an international organization to standardize scientific and technical aspects of pharmaceutical product development and registration. China's participation makes it easier for foreign new drugs to gain entry into China, and for Chinese companies to be marketed outside the country, Shi explained.

    In line with ICH requirements, Chinese pharmaceuticals can file new drug applications to the regulatory agencies of multiple countries and regions under the same technical requirements, greatly saving on the costs of R&D and registration, he said.

    Shi predicts more high-quality Chinese drugs will be going abroad, improving the Chinese pharmaceutical industry's image overseas given the increasing R&D and innovation capabilities of those companies.

    In November, Chinese biomedicine company BeiGene Ltd's cancer treatment Brukinsa (zanubrutinib) capsules gained Accelerated Approval by the FDA under a Breakthrough Therapy designation to treat Mantle Cell lymphoma. The treatment was also granted Orphan Drug designation, "which provides incentives to assist and encourage the development of drugs for rare diseases", the FDA said in a statement.

    It was the first time the agency approved a drug based on efficacy data that came predominantly from China. The approval set a milestone that an innovative therapy from China is allowed to enter the US market.

    Levoamlodipine maleate tablets have been marketed by CSPC Pharmaceutical as Xuanning in China since 2003, and the US regulator's review of the drug was based on the safety and efficacy data collected in China over a five-year period.

    The FDA raised little follow-up inquiries on the clinical data, and also exempted on-site investigation of the company's Chinese factory before approving the drug.

    That showed the US regulator has faith in the company's drug quality management and control system, as quality standards in China's pharmaceutical industry fully met the highest international standards, said Wang Xide, a senior executive of CSPC Pharmaceutical's US arm.

    Top
    BACK TO THE TOP
    English
    Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
    License for publishing multimedia online 0108263

    Registration Number: 130349
    FOLLOW US
    CLOSE
     
    中文字幕不卡高清视频在线| av潮喷大喷水系列无码| yy111111少妇影院里无码| 久久精品中文无码资源站| 精品久久无码中文字幕| 国产成人无码区免费内射一片色欲| 青春草无码精品视频在线观| 无码国产精品一区二区免费vr| 中文字幕在线观看亚洲| 中文字幕无码无码专区| 国产精品成人无码久久久久久 | 久久精品中文字幕一区| 无码精品人妻一区二区三区免费| 无码一区二区三区视频| 精品久久久无码21p发布| 国产资源网中文最新版| 人妻丰满av无码中文字幕| 亚洲国产av无码精品| 国产精品一区二区久久精品无码 | 久久久无码精品亚洲日韩蜜臀浪潮| 中文字幕不卡亚洲| 无码内射中文字幕岛国片| 欧美巨大xxxx做受中文字幕| 亚洲一级特黄大片无码毛片 | 无码人妻丰满熟妇区五十路| 国产精品无码a∨精品| 人妻AV中出无码内射| 日韩AV无码中文无码不卡电影| 亚洲 无码 在线 专区| 亚洲国产av无码精品| 中中文字幕亚洲无线码| 中文字幕亚洲欧美日韩2019| 亚洲精品无码专区2| 中文字幕无码精品三级在线电影 | 四虎影视无码永久免费| 中文字幕无码一区二区三区本日 | 熟妇人妻系列aⅴ无码专区友真希| 韩国三级中文字幕hd久久精品| 最近免费中文字幕mv电影| 久久五月精品中文字幕| 无码粉嫩小泬无套在线观看 |